8-K: XBiotech CEO Simard Retires, Shivaswamy Interim CEO

XBiotech Inc. announced the retirement of CEO John Simard, effective December 8, 2025, with Chief Scientific Officer Sushma Shivaswamy appointed as interim CEO.

Summary

• John Simard notified the Board of Directors on December 5, 2025, of his intent to retire from his role as President and Chief Executive Officer, effective December 8, 2025.
• Mr. Simard will continue to serve as Chairman of the Board of Directors and will provide guidance and assistance to the Company in a consulting role.
• The Company intends to pay the Severance Amount described in Section 8(b) of Mr. Simard's Executive Employment Agreement.
• Sushma Shivaswamy, 47, who has served as XBiotech's Chief Scientific Officer since November 2017, has been appointed as the Company's interim CEO, effective December 8, 2025.
• Dr. Shivaswamy will also continue to serve in her role as Chief Scientific Officer.
• Her annual base salary will be increased to $750,000 while she serves in both roles, with a bonus structure and full remuneration package to be determined by the Compensation Committee at a later time.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the planned nature of the CEO transition, the retention of the former CEO in a strategic role, and the appointment of an experienced internal candidate as interim CEO. However, the uncertainty of an interim period and the search for a permanent CEO prevent a higher score.

Positives

• Continuity of leadership is maintained with John Simard remaining as Chairman of the Board and providing consulting guidance on clinical, scientific, and strategic initiatives.
• An experienced internal candidate, Dr. Sushma Shivaswamy, who has been Chief Scientific Officer since November 2017, was appointed as interim CEO, ensuring familiarity with company operations and strategy.
• The Board expressed confidence in Dr. Shivaswamy's ability to lead the Company seamlessly during the interim period.

Negatives

• The departure of a long-serving CEO (21 years of leadership) could introduce a degree of uncertainty during the transition period.
• The interim nature of the CEO appointment means the Company will undergo a search for a permanent replacement, which can be a lengthy process.
• The Company will incur a severance payment to the outgoing CEO, John Simard.

Risks

• Potential for disruption or uncertainty during the transition period while the Company searches for and appoints a permanent CEO.
• The Compensation Committee still needs to determine the full remuneration package for the interim CEO, which could impact future compensation expenses.

Future Outlook

The Board is confident that Dr. Shivaswamy will lead the Company seamlessly during the interim period before a permanent CEO is appointed.

Management Comments

• The Board thanks Mr. Simard for his 21 years of leadership.
• The Board looks forward to his continued support of the Company's mission in his new role.
• The Board is confident that Dr. Shivaswamy will lead the Company seamlessly during the interim period before a permanent CEO is appointed.

Industry Context

This announcement reflects a common practice in the biotechnology industry where leadership transitions often involve internal promotions to maintain continuity, especially in scientific roles, while a search for a permanent CEO is conducted. The retention of the former CEO in a Chairman and consulting role is also a strategy to leverage institutional knowledge during a transition.

Management Changes

Stakeholder Impact

• Shareholders: Potential for short-term uncertainty due to leadership transition, but continuity provided by former CEO remaining as Chairman and an experienced internal interim appointment.
• Employees: Dr. Shivaswamy's internal promotion may offer stability and career path visibility for scientific staff.
• Customers/Partners: Unlikely to see immediate operational impact given the interim nature and internal promotion, suggesting continuity in ongoing projects.

Next Steps

• The Compensation Committee will determine a bonus structure and full remuneration package for Dr. Sushma Shivaswamy.
• The Company will search for and appoint a permanent Chief Executive Officer.
• The Company intends to pay the Severance Amount to Mr. Simard within the specified time period.

Key Dates

Recommendation

The departure of a long-standing CEO introduces a degree of uncertainty, but the planned nature of the transition, the former CEO's continued involvement as Chairman and consultant, and the appointment of an experienced internal Chief Scientific Officer as interim CEO suggest a measured approach. Investors should hold to observe the performance under interim leadership and await the announcement of a permanent CEO and the strategic direction under new permanent leadership before making significant investment decisions.

Keywords

XBiotech, CEO retirement, interim CEO, John Simard, Sushma Shivaswamy, corporate governance, executive change, biotech management